Bayer AG finally removed a major overhang on 24 June with the announcement that it has come to agreements to settle litigation it took on through the acquisition of agriculture company Monsanto Co. for $66bn in 2018. The uncertainty over how much Bayer eventually would pay out to resolve these lawsuits has impacted the company’s value as investors worried it would not have the capacity to invest in growth, particularly in its pharmaceuticals business, but executives insist this is now not the case.
Bayer will pay $10.1bn-$10.9bn to resolve the majority of lawsuits claiming that weed-killer Roundup causes non-Hodgkin lymphoma and up to...








